Ubs Group Ag Graphite Bio, Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$2.24 - $2.66 $33,732 - $40,056	15,059 Added 96.21%	30,712 $80,000
Q3 2023 Nov 09, 2023	SELL	$2.18 - $2.77 $9,374 - $11,911	-4,300 Reduced 21.55%	15,653 $38,000
Q2 2023 Aug 11, 2023	BUY	$2.47 - $3.38 $27,135 - $37,132	10,986 Added 122.52%	19,953 $51,000
Q1 2023 May 12, 2023	BUY	$1.85 - $3.21 $13,765 - $23,885	7,441 Added 487.61%	8,967 $21,000
Q3 2022 Nov 10, 2022	SELL	$2.82 - $4.24 $131,682 - $197,991	-46,696 Reduced 96.84%	1,526 $5,000
Q2 2022 Aug 10, 2022	BUY	$2.14 - $5.23 $91,876 - $224,539	42,933 Added 811.74%	48,222 $132,000
Q1 2022 May 16, 2022	SELL	$5.1 - $13.06 $13,219 - $33,851	-2,592 Reduced 32.89%	5,289 $27,000
Q4 2021 Feb 14, 2022	BUY	$8.41 - $16.71 $45,178 - $89,766	5,372 Added 214.11%	7,881 $98,000
Q3 2021 Nov 15, 2021	BUY	$15.81 - $28.39 $39,667 - $71,230	2,509 New	2,509 $41,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.